Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): Individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group

Annals of Oncology

Volumn 24, Issue 12, 2013, Pages 3051-3055

  Giessen, C ^a   Graeven, U ^b   Laubender, R P ^c,d   Modest, D P ^a   Schulz, C ^a   Porschen, R ^e   Schmiegel, W ^f,g   Reinacher Schick, A ^h   Hegewisch Becker, S ⁱ   Stintzing, S ^a   Heinemann, V ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Krankenhaus St Franziskus   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF MUNICH   (Germany)

^e Hospital Bremen East   (Germany)

^f RUHR UNIVERSITY BOCHUM   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h ST JOSEF HOSPITAL   (Germany)

ⁱ UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

60 day mortality; First line chemotherapy; Metastatic colorectal cancer; Prognostic factors; Randomised trials

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SURVIVAL TIME;

60-DAY MORTALITY; FIRST-LINE CHEMOTHERAPY; METASTATIC COLORECTAL CANCER; PROGNOSTIC FACTORS; RANDOMISED TRIALS;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84888816219     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt402     Document Type: Article

References (19)

1. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010; 340: c332.
2. Adams RA, Meade AM, Seymour MT et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol 2011; 12: 642-653.
3. Cassidy J, Clarke S, Diaz-Rubio E et al. XELOX versus FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results. Br J Cancer 2011; 105: 58-64.
4. Souglakos J, Ziras N, Kakolyris S et al. Randomised phase-II trial of CAPIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with unresectable/metastatic colorectal cancer. Br J Cancer 2012; 106: 453-459.
5. Köhne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
6. Giessen C, Stintzing S, Laubender RP et al. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011; 10: 317-324.
7. Diaz R, Aparicio J, Molina J et al. Clinical predictors of severe toxicity in patients treated with combination chemotherapy with irinotecan and/or oxaliplatin for metastatic colorectal cancer: a single center experience. Med Oncol 2006; 23: 347-357.
8. Moosmann N, von Weikersthal LF, Vehling-Kaiser U et al. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC study group. J Clin Oncol 2011; 29: 1050-1058.
9. Porschen R, Arkenau HT, Kubicka S et al. Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group. J Clin Oncol 2007; 25: 4217-4223.
10. Schmiegel W, Reinacher-Schick A, Arnold D et al. Capecitabine/irinotecan or capecitabine/oxaliplatin in combination with bevacizumab is effective and safe as first-line therapy for metastatic colorectal cancer: a randomized phase II study of the AIO colorectal study group. Ann Oncol 2013; 24: 1580-1587.
11. Fischer von Weikersthal L, Schalhorn A, Stauch M et al. Phase III trial of irinotecan plus infusional 5-fluorouracil/folinic acid versus irinotecan plus oxaliplatin as first-line treatment of advanced colorectal cancer. Eur J Cancer 2011; 47: 206-214.
12. Rothenberg ML, Meropol NJ, Poplin EA et al. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001; 19: 3801-3807.
13. Chibaudel B, Bonnetain F, Tournigand C et al. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study. Oncologist 2011; 16: 1228-1238.
14. Goldberg RM, Tabah-Fisch I, Bleiberg H et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 2006; 24: 4085-4091.
15. SanoffHK, Sargent DJ, Campbell ME et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol 2008; 26: 5721-5727.
16. Sargent DJ, Kohne CH, SanoffHK et al. Pooled safety and efficacy analysis examining the effect of performance status on outcomes in nine first-line treatment trials using individual data from patients with metastatic colorectal cancer. J Clin Oncol 2009; 27: 1948-1955.
17. Proctor MJ, McMillan DC, Morrison DS et al. A derived neutrophil to lymphocyte ratio predicts survival in patients with cancer. Br J Cancer 2012; 107: 695-699.
18. Kohne CH, Cunningham D, Di Costanzo F et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
19. Glare P, Virik K, Jones M et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003; 327: 195-198.